

















Raymond T. Yan 







A THESIS SUBMITTED 
 
 




DEPARTMENT OF CHEMISTRY 








I would like to start off by thanking Ambalika Sagarika Khadria for her timely and 
practical advice as a sympathetic friend over a phone conversation during my uncertainty 
regarding the drafting of this thesis. I am grateful to her for helping me reconcile my 
Singapore experience, my idealisms, and shortcomings at a decisive moment through a 
realization that pursuit of science is not just all about theories and idealisms. With that 
note, I am fortunate and happy to now have the opportunity to formally thank so many 




I want to, of course, thank Dr. Kim Chu Young, my co-supervisor, for providing me the 
opportunity to work on the multivalent project. I appreciated his patience with me as 
well as his persistent reminders of deadlines, weekly reports, and periodic write-ups. His 
persistence as a supervisor has helped me tremendously in drafting this thesis. I truly 
thank him for giving me an opportunity to get a better sense for science research and 
providing a lab environment where I could learn to understand my own weaknesses and 




I want to thank Dr. Huaqiang Zeng, my main supervisor, for working with me during my 
candidature. I appreciate his flexibility and willingness to accommodate my research 
pursuits during my candidacy. 
ii  
Thank you to Dr. Kinya Hotta for keeping the lab running as smoothly as possible so that 
everyone’s projects could progress without too much hiatus. I want to thank Michelle in 
PPC for her mass spectrometry services, especially her willingness to do last minute 
MALDI-TOF MS on my samples. I want to thank Saytin in PPC for allowing me to 




I want to thank our collaborator, Dr. Ludvig Sollid, in Norway. In particular, I want to 
thank Elin Bergseng for performing the biological assays and communicating the data 




I want to thank Dr. Martin Lear and Dr. Xue Feng for being on my thesis committee and 
their support during my candidature. I would like to extend my thanks to NUS chemistry 
department for providing me the research scholarship so that I can conduct the research 




I want to thank a very helpful labmate and a very good friend, Sathya Dev Undurthi. He 
has made my experience in Singapore a memorable one to say the least. I know for sure 
my life in Singapore would have been much more difficult and intolerable if I didn’t have 




A big thank you to my friend, Priya Jayaraman, for being a buddy both in and out of the 
lab. When lab work was tedious, Priya was a great person to banter with to relieve stress. 
And I appreciate her occasional South Indian home cooking. 
iii  
 
I want to thank my friend Ashish Maurya for stopping by the lab and providing comical 
relief. I am appreciative of his attempts to remind me that having a social life is healthy 





I want to thank my friend, Nyugen Ngoc Bao Tram, for her unrelenting commitment to 
offer her assistance. I am grateful to be on the receiving end of her generosity in various 





I would like to thank Mingzhu and Xi for contributing to the lab environment. I want to 
mention a thank you to Anand for his kindness and help, especially during my departure 




Finally, I need to thank Sandy Chadwick for being my family away from home when I 
first arrived in Singapore to pursue my candidature at NUS. Without her help, it would 
not have been a smooth beginning at NUS. I dedicate this thesis to those that I have 
come to known in Singapore who truly care about helping someone full of naïve 
idealisms to survive in a real world. I deeply appreciate their acts of kindness and care 
that was given to me. 
iv  





Table of Contents iv 
Summary viii 
Chapter 1: Introduction 1 
1.1 Molecular target: HLA-DQ2 association 3 
 
1.2 HLA-DQ2 epitope: Wheat gluten peptides 4 
 
1.2.1 Immunogenic Gluten peptide: α-I gliadin epitope 6 
 
1.2.2 Cellular Response Modulations from Gliadins 7 
 
1.2.3 Biological Toxicity of Gliadins 7 
 
1.3 MHC Peptide Blocker 8 
 
1.3.1 α-I gliadin-based Rational Design 9 
 
1.3.2 Important Factors in Construction of MHC Peptide 
Blocker 10 
 
1.3.3 Mode of Action in MHC Blockade 10 
 
1.4 Multivalent Principle 11 
 
1.4.1 Maleimide Peptide Cross-linking 13 
 
1.4.2 Disulfide Peptide Cross-linking 14 
 
1.4.3 Vinylsulfone Peptide Cross-linking 15 
 
1.4.4 G0 and G1 PAMAM Dendrimer Bifunctional Peptide 
Cross-linking 16 
 
1.5 Solid Phase Peptide Synthesis (SPPS) 18 
 
1.6 Specific Aim of Project 21 
v  
 
Chapter 2: Materials and Methods 
 
2.1 Synthesis of Peptides/MAPs on Solid-phase Support 23 
 




2.1.2 Synthesis of NH2-GASGPFPQPELPYG MAPs 
(multiple antigen peptides) 24 
 
2.2 HPLC Purification (analytical and crude isolation) 25 
 
2.3 Analytical Mass Spectrometry 26 
 
2.4 Synthesis of Multivalent Constructs 
 






































































2.4.10 Synthesis of CGASGPFPQPELPYG TMEA 
Trimer (N-terminus linked) 30 
 
2.4.11 Synthesis of GASGPCPQPELPYG TMEA 
Trimer (P2-residue linked) 31 
 
2.4.12 Synthesis of GASGPFPQPELPYGC TMEA 
Trimer (C-terminus linked) 31 
 
2.4.13 Synthesis of NH2-GASGPFPQPELPYG MAPs 
(multiple antigen peptides) 32 
 
2.4.14 Synthesis of CGASGPFPQPELPYG 
G0 Tetramer (N-terminus linked) 32 
 
2.4.15 Synthesis of GASGPCPQPELPYG 
G0 Tetramer (P2-residue linked) 33 
 
2.4.16 Synthesis of GASGPFPQPELPYGC 
G0 Tetramer (C-terminus linked) 33 
 
2.4.17 Synthesis of CGASGPFPQPELPYG 
G1 Octamer (N-terminus linked) 34 
 
2.4.18 Synthesis of GASGPCPQPELPYG 
G1 Octamer (P2-residue linked) 35 
 
2.4.19 Synthesis of GASGPFPQPELPYGC 
G1 Octamer (C-terminus linked) 35 
 
2.5 Competitive Binding Assay 36 
 




Chapter 3: Results and Discussion 
 
3.1 Competitive Binding Assay on α-I gliadin Analogs 38 
 
3.2 T cell Proliferation Assay on α-I gliadin Analogs 39 
 
3.3 Multivalent Library/ Purity and Yield 40 
 
3.4 Biological Assay on Multivalent Library 
 
3.4.1 T cell Proliferation Assay on Multivalent Library 48 
vii  
 
3.4.2 Antigen-Presentation Inhibition Assay 









Antigen-Presentation Inhibition Assay 











APPENDIX A: Analytical HPLC 60 
 
APPENDIX B: MALDI-TOF MS 69 
 



















The aim of this project is to design multivalent MHC blockers as competitive 
inhibitors of HLA-DQ2 antigen presentation. The implications of such inhibitors serve 
as a therapeutic agent towards the onset of autoimmunity in celiac disease. Our initial 
approach is to create a small multivalent library consisting of dimers, trimers, tetramers, 
and octamers. These multivalent constructs are covalently linked to an α-I gliadin analog 
(wheat gluten peptide) through a thiol-reactive core molecule (i.e. multivalent linkers). 
These multivalent constructs will be used to test the multivalent hypothesis, which 
assumes that a molecule with more copies of binding ligand will favor its binding 
affinity. To verify such hypothesis, biochemical binding assay with HLA-DQ2 will be 
performed, followed by T cell proliferation assay to measure blocking efficiencies. This 
study begins to address the important issue regarding structural optimization (i.e. linker 
length and valency) in rational design for achieving competitive MHC blocking through a 
multivalent strategy. 
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Chapter 1: Introduction 
 
Celiac disease is an autoimmune disorder of the intestinal mucosa.  This disorder 
was first broadly recognized in the second century AD by Aretaeus who described it as a 
malabsorption syndrome.  In 1888, the first modern account of the disease was published 
in a paper, “On the Coeliac Affection Characteristic”.  It mentions that “the allowance of 
farinaceous foods must be small” and the patient can only be cured through means of a 
diet (Hourigan, 2006).  Histological findings of this disease include villous atrophy, crypt 
hyperplasia, and intraepithelial lymphocytosis. If chronic symptoms persist, the increased 
risk of more life-threatening complications such as intestinal adenocarcinoma and 
enteropathy-associated T-cell lymphoma can result.   Other associated diseases include 
Down’s syndrome, Turner’s syndrome,  and  Type  1  diabetes. Celiac patients may 
experience diarrhea, abdominal distention, failure to thrive, neurological symptoms 
(depression), and anemia from chronic disease progression (Green, 2007). 
 
Celiac pathogenesis has been associated with ingestion of gluten found in wheat. 
Oral tolerance is lost as a result of a food antigen.  Celiac patients have abnormal CD4
+ 
T 
cell-initiated immune response towards gluten in the gut lumen.  Gluten-specific T cells 
isolated from celiac lesions produce predominantly interferon-γ (IFN-γ).  Other cytokines 
that are involved in celiac disease are IFN-α and IL-18.  It is possible that IFN-α plays a 
role in the activation of TH1-cell development in celiac disease and drives the 
immunopathology. Interestingly,  tissue  transglutaminase  (TG2)  promoter  contains 
response elements for the pro-inflammatory cytokines IL-6 and tumour-necrosis factor 
(TNF).  An increase in levels of serum antibodies to gluten and autoantigens in celiac 
patients can suggest an adaptive immune response.  Modern serological testing for IgA 
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anti-tissue transglutaminase (tTG) antibody or indirect immunofluorescence assays for 
IgA endomysial antibody are considered highly accurate in diagnosis with high 
sensitivities and specificity.  Interactions made between TG2 and gluten peptides create a 
hapten-carrier-like complex, and with the help of gluten-specific T cells, TG2-specific B 
cells produce TG2-specific antibody (Hourigan, 2006). 
 
Before the mechanisms of the adaptive immunity initiate in celiac patients, a loss 
of integrity in the gut epithelium between the lumen and the lamina propria establishes a 
“pro-inflammatory” environment.  Wheat gluten induces production of intestinal peptide 
zonulin, which acts on tight junctions and increases epithelial permeability.  Leakage of 
“non-self” antigens from the gut lumen activates the innate immune response. The 
resulting adverse autoimmune response is evoked onto the intestinal lumen where T 
lymphocytes  attack  the  epithelial  lining  of  the  intestinal  tract.  Celiac  pathogenesis 
appears to illicit an innate immune response as well as a complex adaptive immune 
response. However, the prospects of understanding how gluten antigen serves as an 





Figure 1: Depiction of the intestinal mucosa during development of Celiac disease 




1.1 Molecular target: HLA-DQ2 association 
 
Gluten had been identified as the exogenous antigen promoting celiac disorder, 
but further studies are needed to understand the mechanism by which this antigen is 
recognized in the body.  Celiac disease can be thought of as a multi-factorial disorder 
involving an environmental component such as a gluten-containing diet, but also includes 
a genetic association to certain HLA allele subtypes.  HLA molecules are MHC (Major 
Histocompability Complex) class II molecules presented on cell membranes that interact 
with peptide fragments referred to as epitopes.  This epitope-MHC complex acts as an 
antigen-presentation signal to T cells.  Almost all affected celiac patients have genotype 
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for the HLA-DQ2 and/or HLA-DQ8 allele. In the European white population, common 
haplotype alleles found in celiac patients are HLA-DQA1*05 and DQB1*02 for DQ2 
molecules, whereas for DQ8 molecules, HLA-DQA1*03 and DQB1*0302 alleles are 
found. Without  these  allele  HLA  haplotypes,  there  is  no  risk  of  celiac  disorder. 
Although, in general, the HLA-DQ2 or DQ8 alleles are deemed necessary, it is not 
sufficient for the development of celiac disease.   MHC is a set of linked genes found 
among  a  3.5  million  base  pair  region  on  the  short  arm  of  human  chromosome  6 
(Hourigan, 2006).  Class II MHC molecules consist of a heterodimeric complex of a two- 
domain 32-34-kDa α-chain and a two-domain 29-32-kDa β-chain. The highest risk for 
disease development is from individuals who express HLA-DQ2 dimers in cis or trans 
(HLA-DR3/DQ2 homozygous or HLA-DR3/7DQ2). In 1993, a paper by Lundin had 








adult celiac disease patients stimulated with gliadin (Lundin, 
 
1993). Gliadins are digested, alcohol-soluble peptide fragments from wheat  gluten, 
which  have  been  identified  to  be  epitopes  for  HLA-DQ antigen-presentation. The 
proliferative T-lymphocyte response can be inhibited by blocking HLA-DQ2 with anti- 
HLA-DQ2 antibodies.   It was demonstrated by Yvonne Van de Wal and collaborators 
that HLA-DQ2 peptide-binding motif had a preference for negatively charged residues at 
several positions (Van de Wal, 1998). 
 
1.2 HLA-DQ2 epitope: Wheat gluten peptides 
 
The immunogenic epitope binding to HLA-DQ2 is located within the p56-75 
region of A-gliadin.   A-gliadin is a peptide fragment of the wheat gluten protein.   In 
celiac patients, the recognition of different epitopes from different gliadins is found with 
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the various T cell clone population.  It has been assumed that the N-terminal part of α-I 
gliadin is able to promote disease activity (Weiser, 1984; de Ritis, 1988).  From wheat 
cultivar Scout 66, the overlapping peptides in the 58 N-terminal amino acids region were 
found to bind DQ2, but showed very weak or no binding to DR3.  The α-I gliadin 21-40 
peptide bound to DQ2 with the highest affinity (Johansen, 1996). However, the N- 
terminal overlapping α-I gliadin peptides were shown to have no stimulatory effects on 
any of their assayed gliadin specific TCC populations from small intestinal mucosa of 
CD patients. These peptides showed negligible inhibition to TCC reactivity in  the 
presence of stimulatory α-I gliadin 31-49 peptide. Through incremental single amino 
acid deletions from the N-terminal or the C-terminal end of the α-I gliadin 31-49 peptide, 
the truncated versions of this peptide was shown to be able to maintain binding capacity. 
However, the truncated peptides yielded different levels of T cell stimulation compared 
to the native α-I gliadin 31-49 peptide.  It was observed that having proline on either the 
N-terminal or C-terminal end of the truncations appeared to reduce the binding and TCC 
stimulation.  The moderate to weak affinity binding of these truncations could be offset 
by the unfavorable interaction of having a terminal proline in the epitope.  Using fixed 
APCs to stimulate TCC RNnTα33 (T cell clone used in the study), the incubation of α-I 
gliadin 31-49 peptide with fixed APCs at pH 4.9 was significantly better in stimulating 
TCC RNnTα33 compared to incubating the peptide at pH 7.4 condition.  There was a 
correlation between the binding affinity of a non-stimulatory peptide to DQ2 on antigen 
presenting cells and its ability to inhibit TCC reactivity in the presence of α-I gliadin 31- 
49 peptide. Moderate to low affinity non-stimulatory peptides generally exhibit poor 
inhibition to TCC reactivity.  Together, this study addresses two closely related issues 
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regarding the T-cell-mediated immunopathogenesis of CD.  First, there is a wide range 
affinity of disease-associated DQ2 binding to various gliadin peptide fragments that can 
either illicit stimulatory or inhibitory effects on TCC reactivity.  Second, there may be a 
complication behind gut-derived gliadin-specific TCC in epitope heterogeneity. TCC 
reactivity patterns may be dependent on the epitope cocktail rather than one specific 
epitope  recognition. It  is  unclear  how  the  T  cell  activation  from  this  epitope 




1.2.1 Immunogenic Gluten peptide: α-I gliadin epitope 
 
The α-I gliadin epitope, QLQPFPQPELPY, has been shown in a crystal structure 
to have the first N-terminal proline binding in the P1 pocket of the HLA-DQ2 nonamer 
binding register.  The crystal structure was in agreement with the characteristic nonamer 
epitope binding pocket of class II MHCs, although studies have shown that the three 
amino acids prior to the N-terminal proline does play a role in the binding affinity via 
peptide backbone interactions.  Structural information of the HLA-DQ2 suggested that 
positions 70 (Arg) and 71 (Lys) of the β-chain create a preferred binding motif for 
negatively charged peptide residues at the P4, P6, and P7 pockets.  Consistent with the 
role of tissue transglutaminase (TG2) in the increase of gliadin immunogenicity 
(Hourigan, 2006), the deamidation of the gliadin substrate at position 6 Gln to Glu 
improves binding to HLA-DQ. The negatively charged carboxyl side-chain participates 
in an extensive hydrogen-bonding network. Due to the proline-rich sequence of α-I 
gliadin, this epitope is rather protease-resistant.  Therefore, α-I gliadin is considered an 
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The effects of gliadin fragments have a complex influence on the oral tolerance of 
celiac patients.  Not only does gliadin serve as antigen for HLA-DQ2 presentation, but 
studies have shown that gliadin can induce phenotypic and functional maturation of 
dendritic cells (subset of antigen-presenting cells for T cell repertoire).  Some of these 
influences include up-regulation of maturation markers (CD80, CD83, CD86, and HLA- 
DR molecules), increased secretion of chemokines/cytokines (i.e. IL-6, IL-8, IL-10, and 
TNF-α), phosphorylation of cell growth MAPK signal pathways, and down-regulation of 




1.2.3 Biological Toxicity of Gliadins 
 
A toxic epitope mapped to p31-49 of A-gliadin was found to be responsible for 
the rapid villous atrophy seen in celiac lesions.   Jejunal biopsy of celiac patients after 
infusion of 200 mg of the p31-49 peptide resulted in histological changes within six hours 
of infusion (Sturgess, 1994).  Later, it was shown that the p31-49 peptide induced the 
expression of the non-classical MHC molecule MICA on the cell surface of villous 
epithelium. The effect of p31-49 peptide on the upregulation of MICA was demonstrated 
to be mediated by cytokine IL-15.  Mononuclear cells or enterocytes produces IL-15 in 
response to the p31-49 peptide.  The surface levels of MICA appeared to correlate with 
the clinical severity of the disease.  MICA serves as a ligand for the NKG2D receptor. 
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Resident intraepithelial lymphocytes in the gut lumen of celiac patients express NKG2D 





1.3 MHC Peptide Blocker 
The initial onset of celiac disease is presumed to be associated with ingested 
gliadin binding to HLA-DQ molecules on antigen-presenting cells that leads to priming 
of T lymphocytes towards an autoimmune response.  By blocking this occurrence after 
ingestion of gliadin, the adverse reaction of an autoimmune response can be inhibited in 
celiac individuals.  Studies on NOD mice have tested the peptide blocking potential in 
class II MHCs to prevent autoimmune diabetes.  In these studies, investigators were able 
to  demonstrate, through  screening for  a  synthetic peptide,  competitive inhibition  in 
antigen presentation of A
g7  
molecule in vitro. They could inhibit the priming for A
g7
- 
restricted T cell responses in vivo and delay the development of spontaneous autoimmune 
diabetes in the NOD mice (Vaysburd, 1995).  It is noteworthy that in such studies or any 
studies involving the MHC association of an autoimmune disorder, it is necessary to have 
an identifiable antigen before any kind of MHC blockade studies can be conducted. 
Rather than screening for novel peptides as potential MHC peptide blockers (Anderson, 
 
2006), known epitopes for HLA-DQ2 were studied with the intention in developing a 
rational design peptide blocker (Johansen, 1996).  Fortunately, structural data have been 
obtained for antigen-bound HLA-DQ2 molecule.  Crystal structure shows the α- and β- 
chains forming a heterodimeric HLA-DQ2 molecule with an α-I gliadin epitope bound to 




















Figure 2:  Crystal structure of the α-I gliadin epitope bound to the binding groove of the 
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Although peptides have been identified that competitively bind to HLA-DQ2 with 
no  immunogenicity these  peptides  may  lack  the  protease-resistance  or  the  high 
specificity of the native antigen α-I gliadin   Since α-I gliadin has been already studied to 
some extent  it was taken to be a model template sequence in developing a class II MHC 
blocker According to the crystal structure of the α-I gliadin -HLA-DQ2 complex  P2 
residue  (phenylalanine)  side-chain  is  solvent  exposed  (Kim 2004) In  order  to 
implement some degree of rational design  the P2 residue was chosen as a substitution 
position  The rationale behind a single amino acid substitution at the P2 position is to 
obtain an α-I gliadin analog that will have similar binding affinity to the original α-I 
gliadin and block the T cell recognition to MHC presentation  The incentive for a similar 


























































1.3.2 Important Factors in Construction of MHC Peptide Blocker 
 
MHC blockade of HLA-DQ2 with a peptide blocker should prevent the 
presentation of gluten peptides to gliadin-specific T cells, but also not be recognizable by 
any other T cell clones that may arise due to hypersensitivity.  To ensure this, peptide 
blocker should contain relatively big side-chains so that no T cell receptor can dock onto 
HLA-DQ2-peptide  blocker  complex  due  to  steric  hindrance. Since  MHC  peptide 
blockers must persist through the digestive tract in order to target the HLA-DQ2 
molecules on antigen presenting cell surface, they not only need to have high-affinity at 
concentration levels in the intestinal lamina propria, but also have proteolytic stability 




1.3.3 Mode of Action in MHC Blockade 
In a simplistic model, MHC blockers should exhibit binding affinity to MHC 
class II molecules that could out-compete the antigenic peptide.  Hence, such a blocker 
can down-regulate the moiety of MHC class II complexes on antigen-presenting cells 
from  being  immunogenic. However,  it  is  known  that  clusters  of  T  cell  receptor 
(TCR)/CD3 complexes form in parallel with clusters of agonist class II MHC/peptide 
complexes  on  the  surface  of  antigen  presenting  cells  (Chmielowski,  2002). An 
alternative model for inhibition of T cell recognition is the redistribution of agonist and 
null class II MHC/ peptide complexes with antagonist peptides affecting the interface of 
antigen presenting cells with CD4
+  
T cells; more specifically naïve T cells. In this 
alternative model, the inhibition of T cell recognition is not so much involving the 
cumulative effect of independent single blocking events with MHC blockers on MHC- 
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peptide immune complexes.  Rather, it is a redistribution or the change in characteristics 
of a cluster/population of MHC-peptide immune complexes that affects the interface 
compatibility with a T cell. This would imply that inhibition of T cell recognition 
requires interfering with the intrinsic ability of agonist peptide/MHC complexes from 
forming appropriate interfaces for T cell recognition. Moreover, such an inhibition 
would require more than just independent MHC blocking events, which is less likely to 
affect neighboring MHC molecules from undergoing proper interface formation with 
agonist peptides. Therefore,  the  two  models  aforementioned  suggest  that  the 
effectiveness of MHC blockade occurs in two-fold:   competitive binding of a blocker 
peptide to its targeted MHC over the antigenic peptide and a multi-level inhibitory 
mechanism that can account for the intrinsic surface dynamics of multiple antigenic 
peptide/MHC complexes to  form favorable interfaces for T  cell  docking. A  MHC 
blockade approach should give importance for targeting MHC clusters rather than 




1.4 Multivalency Principle 
 
In keeping with an effective class II MHC blockade approach, a multivalency 
strategy was implemented in testing MHC blockade on HLA-DQ2 blockade. Studies 
have shown that clustered epitopes in a multivalent fashion can increase the binding 
affinity towards its target receptor. This increase in binding affinity can be attributed to a 
“bind and slide” or internal diffusion mechanism. Essentially, the first micro-affinity 
constant of a multivalent ligand can undergo recapture with the receptor before complete 
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dissociation of the complex. Effectively, the off rate is reduced and overall binding 
affinity of the multivalent ligand-receptor interaction is increased. 
 
Thermodynamically, the free energy of binding for a multivalent ligand is the sum 
of favorable energy of each binding monomer unit, a favorable entropic contribution due 
to fewer rotational and translation degrees of freedom lost in binding when previous 
monomer units are already bound, and an unfavorable term as a result of strain or 
distortion in the multivalent ligand or receptor when achieving the bound state (Dam, 
2008).  Minimizing this strain or distortion in bound state between a multivalent ligand 
and its receptors is critical to maximizing the favorable free energy of binding. 
 
In principle, a multivalent-peptide blocker having an increased binding affinity 
towards HLA-DQ2 can competitively bind over the agonist, α-I gliadin even though the 
“monomeric”  peptide  blocker  may  have  similar  binding  affinity  compared  to  the 
antigenic α-I gliadin.  In addition, the structural architecture from the binding interaction 
between a multivalent-peptide blocker to HLA-DQ2 can result in a steric occlusion of the 
MHC surface to T cell recognition.  Thus, a multivalent-peptide blocker with increased 
binding affinity, steric blocking potential, and multiple MHC targeting can fulfill the 
criteria of an effective and specific HLA-DQ2 blocker. 
 
Synthetic peptide dendrimers are known examples of utilizing the multivalency 
principle for therapeutic treatments.  Synthetic peptide dendrimers have been shown to 
prevent the development of experimental allergic encephalomyelitis in SJL mice with 
pre-treatment before the immunization of monomeric encephalitogenic peptide. This 
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study demonstrates that multiple antigen peptides (MAPs) can be used to elicit robust 
immune response over monomeric forms of a peptide to prevent autoimmune disease 
progression (Wegmann, 2008).  In Section 1.4.4, the formation of multimer constructs 
using PAMAM core dendrimers will be discussed. 
 
 1.4.1 Maleimide Peptide Cross-linking 
 
Maleimide is a five-member ring compound that contains an unsaturated imide. It 
can be formed by treating maleic anhydride with an amine derivativefollowed by 
dehydration.  Maleimides that are connected by a molecular unit are useful cross-linking 
reagents utilized in polymer chemistry.  A common method in formation of a maleimide 
cross-linking reagent undergoes N-alkylation of the imide under Mitsunobu condition. 
The electrophilic nature of the double bond in the maleimide is a major culprit behind 
lower yields  when  attempting  to  synthesize  maleimide-based  cross-linkers. By 
combining Mitsunobu reaction with reversible Diels-Alder reaction (for reversible 
protection of the double bond in maleimides), 1,3,5-tris(hydroxymethyl)benzene as a 
trifunctional core molecular unit reacts with the imide of the maleimide to produce a 
homotrifunctional maleimide based cross-linker (Farha, 2006). 
Maleimides can serve as a core linker with chemoselectivity towards sulfhydryl 
groups.  This selective reactivity is established by neutral or acidic pH. At this pH, thiol 
reactivity is 10
3 
times faster than amine reactivity. The unsaturated maleimide has a 




 In principle, through protein or peptide engineering, thiol-containing cysteines 
can be rationally incorporated into target biomolecules to have predictable cross-linking 
by maleimide-containing cross-linkers. Several other applications have used 
multifunctional  maleimides  as  an  invaluable  biochemical  tool. Homobifunctional 
maleimides have been used as molecular rulers between cross-linked amino acids, to 
facilitate low- protein crystallization, to probe conformational states of proteins, and to 
enhance potency of protein therapeutics in development of enzyme-antibody conjugates. 
Two commercially available maleimide-based cross-linkers (Pierce) were used in the 
study of the multivalent principle:  1,4-bis(maleimido)butane (BMH), a dimer forming 
cross-linker with thioether linkages and Tris-[2-maleimidoethyl]amine (TMEA), a trimer 




1.4.2 Disulfide Peptide Cross-linking 
Disulfide  bonds  are  common  chemical  linkages  found  in  protein  tertiary 
structures. These chemical bonds are formed between two cysteine residues in the 
protein through oxidative reaction between the two sulfhydryl groups of the cysteine side 
chains. Although  disulfide  bonds  are  relatively  stable  at  physiological  pH,  it  is 
susceptible to a reductive reaction where the bond is hydrolsed into two separate 
sulfhydryl groups. A convenient chemical reaction that can yield a disulfide bond is 
through an activation of a sulfhydryl group. An “activated” sulfhydryl group can be 




















The electron-withdrawing pyridine ring results in a weak bond with the sulfhydryl 
group, which would be susceptible to nucleophilic attack.  Another sulfhydryl-containing 
compound can undergo nucelophilic attack of the “activated” sulfhydryl group yielding a 
stable disulfide bond and release of the pyridine-2-thione. This reaction happens at 
neutral pH or a slightly basic pH with a reported ~60% yield efficiency (Cochran, 2000). 
Since the liberated pyridine-2-thione has an absorbance at 344 nm, the extent of reaction 
can be monitored using UV/Vis spectrometry. 
The final epitope dimer is spaced by a crossbridge spacer arm of 19.9 angstroms. 
 
A commercially available cross-linker with “activated” sulfhydryl groups (Pierce) was 
used in the study of the multivalent principle:  1,4-di-[3’-(2’- 





1.4.3 Vinylsulfone Peptide Cross-linking 
An  alternative  chemical  moiety that  can  form  a  stable  sulfhydryl  alkylation 
linkage, aside from the maleimide chemistry described earlier (1.4.1 Maleimide Peptide 
Cross-linking),  is   vinylsulfone  groups. Vinylsulfone groups are susceptible to 
nucleophilic Michael addition reactions.  The sulfone group provides electron resonance 
upon nucleophilic attack that stabilizes the transition state.  The product formation such 









Vinylsulfone is selectively reactive with sulfhydryl groups at pH 7.2-9.2 (Pierce). 
However, at pH 9.5 and greater, vinylsulfone can react with amines and sulfhydryl 
groups leading to potentially unwanted side products.  A mild basic condition of pH 8.0 
with 2% N-methylimidazole in aqueous solution can provide sufficient sulfhydryl 
selectivity in the Michael addition to vinylsulfone. The two epitopes forming stable 
thioether linkages with the HBVS are spaced apart by 14.7 angstroms. A commercially 
available cross-linker with vinylsulfone moiety (Pierce) was used in the study of the 
multivalency principle:  1,6-hexane-bis-vinylsulfone (HBVS), a dimer forming cross-




1.4.4 G0 and G1 PAMAM Dendrimer Bifunctional Peptide Cross-linking 
 
A tetrameric core was formed using succinimidyl-[(N-maleimidopropionamido)- 
tetraethyleneglycol] ester (NHS-PEO4-Maleimide) and G0 polyamidomine (PAMAM) 
dendrimer   [amide   linkage   and   thioether   linkage]. NHS-PEO4-Maleimide  is   a 
heterofunctional linker with a succinimidyl-activated free acid group at one end and a 
thiol-reactive maleimide group at the other end.  The free acid end is primed to react with 
an amine nucleophile to form an amide linkage and the maleimide will react with a 



























             Although both ends of the heterofunctional linker are susceptible to nucleophilic 
attack by indiscriminate nucleophiles, it is possible to tune the selectivity for the respective 
ends by maintaining an optimal pH range and keeping a particular reaction order.  The 
latter point suggests that amine reactivity with the succinimidyl-activated free acid should 
be performed first followed by the thiol addition to the maleimide. The reason that 
this sequence of selective reactions can occur is due to maintaining an optimal range of pH 
7.0.  At this pH range, amine reacts readily with the succinimidyl-activated free  acid  
without  non-selectively  reacting  with  the  maleimide  group.  Once  the 
heterofunctional linker is devoid of the succinimidyl-activated free acid, then the thiol- 
reactive  maleimide can  react  with  the  sulfhydryl containing ligand. Therefore, the 
tetrameric G0 PAMAM dendrimer core was first reacted with NHS-PEO4-Maleimide linker 
followed by Michael addition to the maleimide by the sulfhydryl group of the 
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cysteine-containing  epitope. The  maximal  spacing  distance  between  two  epitope 
linkages  is  68.2  angstroms.  Similarly,  octamer  formation  was  accomplished  with 
succinimidyl-[(N-maleimidopropionamido)-dodecaethyleneglycol] ester (NHS-PEO12- 
Maleimide) and G1 polyamidomine (PAMAM) dendrimer (maximal spacing distance 




1.5 Solid Phase Peptide Synthesis (SPPS) 
 
Peptides were synthesized using standard Fmoc solid phase synthesis. Solid 
phase synthesis on  polymeric resin  support, developed by Merrifield, is  a  common 
chemical strategy to perform chemical couplings while minimizing the need to perform 
reaction workup/purification steps after each subsequent coupling step.   In the case of 
peptide synthesis, the procedure is a series of repetitive steps of amino acid coupling and 
selective removal of the α-carbon amine protection group. The basic principle underlying 
solid phase peptide synthesis can be thought to consist of two main steps: 
activation/coupling of amino acid and deprotection of N-terminal amine of the growing 
peptide chain.  The growing peptide chain is covalently linked to a resin linker that can 
be chemically cleaved under specific conditions (i.e. basic or acidic).   During peptide 
synthesis, the added amino acids are orthogonally protected by stable chemical moieties 
at the α-carbon amine and the potentially reactive side chain functional group.  The α- 
carbon amine is typically protected by either butyloxycarbonyl (BOC) group or 
fluorenylmethoxycarbonyl (FMOC) group.  Depending on whether the chemical stability 
of the peptidyl-linker is stable in basic or acidic conditions, BOC or FMOC protection 
would be used, respectively.  The only possible functional group left on the amino acid 
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that is unprotected and allowed to react is the carboxylic acid group. This carboxylic acid 
group of the subsequent amino acid would undergo a coupling reaction with a free amine 
of the growing peptide chain.  However, a carboxylic acid group does not react readily 
with a free amine to release an H2O molecule.  Therefore, the carboxylic acid group is 
chemically activated by reacting with a good leaving group.  Upon activation, the free 
amine of the growing peptide chain can undergo nucleophilic attack of the activated 
carboxylic acid to form a stable peptidyl bond and with release of the leaving group. 
After coupling of the amino acid, the peptide chain becomes protected at the N-terminal 
amine by either a BOC or FMOC group.  In order to prime the peptide chain for the next 
amino acid coupling step, the N-terminal amine protection is removed (BOC removal can 
be done with hydrogen fluoride/or trifluoroacetic acid and Fmoc removal is accomplished 
by piperidine solution).   Once the N-terminal amine protection group is removed, the 
growing peptide chain is ready for another cycle of amino acid coupling. When the 
intended peptide sequence is made with the final N-terminal amine deprotected, the 
peptide would be isolated by cleaving it off the resin-bound support.  Under the cleavage 
condition, which is orthogonal to the repetitive conditions of amino acid coupling and N- 
terminal  amine  deprotection, the  chemical  moieties of  the  side-chain protection are 
simultaneously removed.  Finally, after synthesis, theThe final result product is to have 
obtained  the  desired  peptide  sequence  in  solution. However,  due  to  the  limited 
efficiencies in amino acid coupling and protection group removal, it is necessary to 
isolate the desired peptide from the crude cleavage mixture using a purification method 
(Chan and White, 2000). 
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1.6 Specific Aim of Study 
 
The primary objective is to inhibit HLA-DQ2 antigen presentation.  Inhibition of antigen 
presentation will minimize the immunogenic response from T cell recognition and  
proliferation. To  achieve  competitive  inhibition  of  antigen  presentation,  a 
multivalent approach is taken.  A peptide is first identified which bind to HLA-DQ2, but 
does not illicit an immunogenic response.  This peptide will be incorporated as a ligand 
into various multimers (i.e. dimers, trimers, tetramers, and octamers) forming a 
multivalent library set.  The multivalent constructs are subjected to T cell proliferation 
assays and antigen presentation inhibition assays to validate the multivalent strategy. It is 
predicted that the increase in valency of the multivalent constructs will result in enhanced 
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binding affinity towards HLA-DQ2 through increase local  concentration effects and 
clustering effects.  Both effects will lead to competitive inhibition of HLA-DQ2 binding 
to native epitopes, Inhibition of HLA-DQ2 antigen presentation through competitive 
multivalent inhibitors can serve as an effective therapeutic for celiac disease.
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2.1 Synthesis of Peptides/MAPs on Solid-phase Support 
 
Fmoc-protected amino acids and  LL Wang resin (100-200 mesh) were from 
Novabiochem, Merck chemicals.  All other solvents and reagents used for solid phase 




2.1.1 Synthesis of NH2-CGASGPFPQPELPYG, NH2-GASGPCPQPELPYG, and 
NH2-GASGPFPQPELPYGC 
 
LL Wang resin (0.30-0.50 mmol/g resin) was swelled in dichloromethane (DCM) 
for at least two hours before transferring resin in DCM to a fritted glass filter (<100 
mesh)  reaction  vessel  (under  vacuum  filtration).  Resin  was  re-suspended  with 
dimethylformamide (DMF)/filtered  five  times. Resin  re-suspended in  DCM/filtered 
once. The subsequent Fmoc-amino acid, 2-(1H-Benzotriazole-1-yl)-1,1,3,3- 
tetramethylaminium hexafluorophosphate (HBTU), and hydroxybenzotriazole (HOBT, 
omitted in the first amino acid coupling reaction) dissolved in 1:1 DMF:DCM with final 
addition of diispropylethylamine to mixture before adding to the resin bed (amino acid, 
HBTU, HOBT, and DIPEA were in five fold excess relative to resin).  Reaction vessel 
was placed on a shaker at ambient temperature and left for 2 hours.   Reaction vessel 
(under vacuum filtration) washed with DMF five times and once with DCM. 20% 
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piperidine in DMF added to the resin bed and incubated for 2 minutes.   Deprotection 
solution removed under vacuum filtration and washed with DCM.  Deprotection repeated 
once more.  Resin bed was washed with DMF five times and once with DCM.  The next 
coupling reaction was carried out in a reiterative manner. The coupling reaction and 
deprotection reaction was followed until the completion of the intended peptide sequence. 
The peptide bound resin was re-suspended in DMF and pipette transferred into 50 mL 
falcon tube. DMF solvent was micro-pipette aspirated from the peptide bound resin. 
DCM added to the peptide bound resin to remove residue DMF solvent. DCM was 
micro-pipette aspirated from the peptide bound resin.  A cleavage solution of 95:2.5:2.5 
TFA:TIS:H2O added to the resin in the 50 mL falcon tube.  Tube was placed on a shaker 
at ambient temperature and left for 3 hours.  Cleavage solution with resin was gravity 
filtrated through Whatman filter paper. Resin was rinsed twice with TFA cleavage 
solution. Filtrate was added drop-wise into 100 mL cold methyl tert-butyl ether (MTBE). 
Precipitate ether  solution  was  aliquoted  into  two  50  mL  falcon  tube. Tubes  were 
centrifuged at 4000 rpm for 10 minutes.  Supernatant was discarded and pellets were air- 
dried overnight. Pellets were dissolved in 1:1 acetonitrile:water and frozen in -80 
0
C then 




2.1.2 Synthesis of NH2-GASGPFPQPELPYG MAPs (multiple antigen peptides) 
 
 
The same procedure was followed as the above solid-phase peptide synthesis, but 
with a pre-loaded resin rather than an empty Wang resin.  A pre-loaded Fmoc-β-alanine- 
Wang resin (100-200 mesh) was treated with 20% piperidine in DMF to remove the 
Fmoc protection of the β-alanine amine instead of coupling the first amino acid.  After 
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deprotection of the amine, (Fmoc)2-lysine amino acid derivative was coupled to the resin 
(the double Fmoc-protection yields two free amine groups after Fmoc removal).   The 
next iteration of amino acid coupling using (Fmoc)2-lysine amino acid provided a 
branched core of four amine groups. The remaining synthesis followed the standard 
solid-phase  peptide  synthesis  procedure  as  described  above  to  obtain  the  desired 
sequence.   (Note:   one modification made to the solid-phase peptide synthesis for the 
MAPs construct was after each amino acid coupling and wash, ~10-20% acetic anhydride 
in 1:1 DMF:DCM was added to the resin and incubated for 5-10 minutes before 
proceeding to another wash and Fmoc removal step. This additional step ensures that any 
free amine groups left uncoupled from the previous amino acid coupling step will be 
acetylated. Hence, this minimizes further side reactions that would produce side products 
of comparable molecular weights to the end product and complicating the purification 
process.) (Refer to section 2.4.13 for purity and actual yields of this synthesis) 
 
 
2.2 HPLC Purification (analytical and crude isolation) 
 
Crude purification was performed with a LC-10 AT VP, class VP HPLC 
instrument using Phenomenex C18 Luna hydrophobic column and Phenomenex Biosep 
S3000 size exclusion column (octamer isolation).  Analytical HPLC was performed with 
a Amersham Ettan LC HPLC instrument using Phenomenex C18 Luna hydrophobic 
column (purity deterimination). 
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2.3 Analytical Mass Spectrometry 
 
Molecular mass determination was performed by using LCMS 2010 EV electron 









2.4.1 Synthesis of CGASGPFPQPELPYG DPDPB Dimer (N-terminus linked) 
 
A solution of 1,4-Di-[2’-pyridyldithio)propionamido]butane (DPDPB) prepared 
by dissolving 1.5 mg DPDPB in 100 uL DMSO. 11.5 mg CGASGPFPQPELPYG 
peptide was dissolved in 400 uL DMSO. DPDPB solution was added to the peptide 
solution, and left the reaction for 12 hours.  Reaction mixture was injected directly into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18  reverse-phase HPLC.  Reported 98.5% pure CGASGPFPQPELPYG DPDPB dimer 
construct was stored at -80
o 




2.4.2 Synthesis of GASGPCPQPELPYG DPDPB Dimer (P2-residue linked) 
 
A solution of 1,4-Di-[2’-pyridyldithio)propionamido]butane (DPDPB) prepared 
by dissolving 1.6 mg DPDPB in 100 uL DMF.  18.2 mg GASGPCPQPELPYG peptide 
was dissolved in 400 uL DMF.  DPDPB solution was added to the peptide solution, and 
left   the   reaction   for   12   hours. Reaction   mixture   was   injected   directly   into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
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0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18  reverse-phase HPLC. Reported 97.7% pure GASGPCPQPELPYG DPDPB dimer 
construct was stored at -80
o 





2.4.3 Synthesis of GASGPFPQPELPYGC DPDPB Dimer (C-terminus linked) 
 
A solution of 1,4-Di-[2’-pyridyldithio)propionamido]butane (DPDPB) prepared 
by dissolving 1.5 mg DPDPB in 100 uL DMF.  11.5 mg GASGPFPQPELPYGC peptide 
was dissolved in 400 uL DMF.  DPDPB solution was added to the peptide solution, and 
left   the   reaction   for   12   hours. Reaction   mixture   was   injected   directly   into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18  reverse-phase HPLC.  Reported 97.4% pure GASGPFPQPELPYGC DPDPB dimer 
construct was stored at -80
o 




2.4.4 Synthesis of CGASGPFPQPELPYG BMH Dimer (N-terminus linked) 
 
A solution of 1,4-bis(maleimido)butane (BMH) prepared by dissolving 0.8 mg 
 
BMH in 100 uL acetonitrile.  18.0 mg CGASGPFPQPELPYG peptide was dissolved in 
 
390 uL distilled water with 10 uL acetic acid.  BMH solution was added to the peptide 
solution, and left the reaction for 12 hours.  Reaction mixture was injected directly into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
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C18  reverse-phase HPLC. Reported 96.5% pure CGASGPFPQPELPYG BMH dimer 
construct was stored at -80
o 




2.4.5 Synthesis of GASGPCPQPELPYG BMH Dimer (P2-residue linked) 
 
A solution of 1,4-bis(maleimido)butane (BMH) prepared by dissolving 0.5 mg 
 
BMH in 100 uL acetonitrile.  10.9 mg GASGPCPQPELPYG peptide was dissolved in 
 
390 uL distilled water with 10 uL acetic acid.  BMH solution was added to the peptide 
solution, and left the reaction for 12 hours.  Reaction mixture was injected directly into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18   reverse-phase HPLC. Reported 98.2%  pure  GASGPCPQPELPYG BMH  dimer 
construct was stored at -80
o 




2.4.6 Synthesis of GASGPFPQPELPYGC BMH Dimer (C-terminus linked) 
 
A solution of 1,4-bis(maleimido)butane (BMH) prepared by dissolving 0.8 mg 
 
BMH in 100 uL acetonitrile.  18.0 mg GASGPFPQPELPYGC peptide was dissolved in 
 
390 uL distilled water with 10 uL acetic acid.  BMH solution was added to the peptide 
solution, and left the reaction for 12 hours.  Reaction mixture was injected directly into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18  reverse-phase HPLC. Reported 96.0% pure GASGPFPQPELPYGC BMH dimer 
construct was stored at -80
o 
C. Average yields obtained were 12%. 
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2.4.7 Synthesis of CGASGPFPQPELPYG HBVS Dimer (N-terminus linked) 
 
A solution of 1,6-hexane-bis-vinylsulfone (HBVS) prepared by dissolving 0.3 mg 
 
HBVS in 50 uL acetonitrile.  7.3 mg CGASGPFPQPELPYG peptide was dissolved in 
440 uL distilled water with 10 uL N-methylimidazole.  HBVS solution was added to the 
peptide solution, and left the reaction for 12 hours. Reaction mixture was injected 
directly into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical  C18   reverse-phase  HPLC. Reported  96.8%  pure  CGASGPFPQPELPYG 
HBVS dimer construct was stored at -80
o 





2.4.8 Synthesis of GASGPCPQPELPYG HBVS Dimer (P2-residue linked) 
 
A solution of 1,6-hexane-bis-vinylsulfone (HBVS) prepared by dissolving 0.8 mg 
 
HBVS in 50 uL acetonitrile.  18.1 mg GASGPCPQPELPYG peptide was dissolved in 
440 uL distilled water with 10 uL N-methylimidazole.  HBVS solution was added to the 
peptide solution, and left the reaction for 12 hours. Reaction mixture was injected 
directly into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical C18 reverse-phase HPLC.  Reported 97.5% pure GASGPCPQPELPYG HBVS 
dimer construct was stored at -80
o 
C. Average yields obtained were 35%. 
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2.4.9 Synthesis of GASGPFPQPELPYGC HBVS Dimer (C-terminus linked) 
 
A solution of 1,6-hexane-bis-vinylsulfone (HBVS) prepared by dissolving 0.8 mg 
 
HBVS in 50 uL acetonitrile.  18.2 mg GASGPFPQPELPYGC peptide was dissolved in 
440 uL distilled water with 10 uL N-methylimidazole.  HBVS solution was added to the 
peptide solution, and left the reaction for 12 hours. Reaction mixture was injected 
directly into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical  C18   reverse-phase  HPLC. Reported  96.2%  pure  GASGPFPQPELPYGC 
HBVS dimer construct was stored at -80
o 





2.4.10 Synthesis of CGASGPFPQPELPYG TMEA Trimer (N-terminus linked) 
A solution of Tris-[2-maleimidoethyl]amine (TMEA) prepared by dissolving 0.5 
mg  TMEA  in  100  uL  acetonitrile. 11.0  mg  CGASGPFPQPELPYG  peptide  was 
dissolved in 390 uL distilled water with 10 uL acetic acid.  TMEA solution was added to 
the peptide solution, and left the reaction for 12 hours.  Reaction mixture was injected 
directly into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical  C18   reverse-phase  HPLC. Reported  97.8%  pure  CGASGPFPQPELPYG 
TMEA trimer construct was stored at -80
o 
C. Average yields obtained were 40%. 
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2.4.11 Synthesis of GASGPCPQPELPYG TMEA Trimer (P2-residue linked) 
A solution of Tris-[2-maleimidoethyl]amine (TMEA) prepared by dissolving 0.8 
mg TMEA in 100 uL acetonitrile.  18.2 mg GASGPCPQPELPYG peptide was dissolved 
in 390 uL distilled water with 10 uL acetic acid. TMEA solution was added to the 
peptide solution, and left the reaction for 12 hours. Reaction mixture was injected 
directly into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical C18 reverse-phase HPLC.  Reported 96.6% pure GASGPCPQPELPYG TMEA 
trimer construct was stored at -80
o 





2.4.12 Synthesis of GASGPFPQPELPYGC TMEA Trimer (C-terminus linked) A 
solution of Tris-[2-maleimidoethyl]amine (TMEA) prepared by dissolving 0.7 mg TMEA 
in 100 uL acetonitrile. 18.3 mg GASGPFPQPELPYGC peptide was dissolved in 
390 uL distilled water with 10 uL acetic acid. TMEA solution was added to the peptide 
solution, and left the reaction for 12 hours. Reaction mixture was injected directly into 
semipreparative C18 reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA. Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18 reverse-phase HPLC. Reported 96.0% pure GASGPFPQPELPYGC TMEA trimer 
construct was stored at -80
o 
C. Average yields obtained were 50%. 
32  
2.4.13 Synthesis of NH2-GASGPFPQPELPYG MAPs (multiple antigen peptides) 
Dried pellet was dissolved in 5-10% DMF in 70:30 H2O: acetonitrile and injected 
directly into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical C18  reverse-phase HPLC.  Reported 94.8% pure NH2-GASGPFPQPELPYGC 
MAPs tetramer construct was stored at -80
o 





2.4.14 Synthesis of CGASGPFPQPELPYG G0 Tetramer (N-terminus linked) 
 
A linker solution of succinimidyl-[(N-maleimidopropionamido)- 
tetraethyleneglycol] ester (NHS-PEO4-Maleimide) prepared by dissolving 3.0 mg NHS- 
PEO4-Maleimide in 200 uL acetonitrile and 100 uL distilled water.  At 2 hour intervals, 2 
uL of 20% G0 polyamidomine (G0 PAMAM) dendrimer in methanol was added into the 
linker solution.  A total of 8 uL G0 PAMAM solution was added into the linker solution. 
22.0 mg CGASGPFPQPELPYG peptide was dissolved into 400 uL distilled water and 
 
100 uL acetonitrile with 14 uL acetic acid.   Linker solution was added to the peptide 
solution, and left the reaction for 12 hours.  Reaction mixture was injected directly into 
semipreparative C18  reverse-phase HPLC column using water-acetonitrile gradient in 
0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry sample. 
Mass determination was confirmed by MALDI-TOF MS and purity check by analytical 
C18  reverse-phase HPLC. Reported 98.3% pure CGASGPFPQPELPYG G0 tetramer 
construct was stored at -80
o 
C. Average yields obtained were 7%. 
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2.4.15 Synthesis of GASGPCPQPELPYG G0 Tetramer (P2-residue linked) 
 
A linker solution of succinimidyl-[(N-maleimidopropionamido)- 
tetraethyleneglycol] ester (NHS-PEO4-Maleimide) prepared by dissolving 6.0 mg NHS- 
PEO4-Maleimide in 200 uL acetonitrile and 100 uL distilled water.  At 1 hour intervals, 2 
uL of 20% G0 polyamidomine (G0 PAMAM) dendrimer in methanol was added into the 
linker solution. A total of 12 uL G0 PAMAM solution was added into the linker solution. 
38.8 mg GASGPCPQPELPYG peptide was dissolved into 400 uL distilled water with 14 
uL acetic acid. Linker solution was added to the peptide solution, and left the reaction for 
6 hours.  Reaction mixture was injected directly into semipreparative C18  reverse-phase 
HPLC column using  water-acetonitrile gradient  in  0.05-0.04% (v/v) TFA. Purified 
product peak collected and lypholized as dry sample.  Mass determination was confirmed 
by MALDI-TOF MS and purity check by analytical C18 reverse-phase HPLC.  Reported 
95% pure GASGPCPQPELPYG G0 tetramer construct was stored at -80
o  
C.  Average 
 





2.4.16 Synthesis of GASGPFPQPELPYGC G0 Tetramer (C-terminus linked) 
 
A linker solution of succinimidyl-[(N-maleimidopropionamido)- 
tetraethyleneglycol] ester (NHS-PEO4-Maleimide) prepared by dissolving 6.0 mg NHS- 
PEO4-Maleimide in 200 uL acetonitrile and 100 uL distilled water.  At 3 hour intervals, 2 
uL of 20% G0 polyamidomine (G0 PAMAM) dendrimer in methanol was added into the 
linker solution.  A total of 6 uL G0 PAMAM solution was added into the linker solution. 
35.3 mg GASGPFPQPELPYGC peptide was dissolved into 400 uL distilled water with 
 
14 uL acetic acid.  Linker solution was added to the peptide solution, and left the reaction 
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for 6 hours.   Reaction mixture was injected directly into semipreparative C18  reverse- 
phase HPLC column using water-acetonitrile gradient in 0.05-0.04% (v/v) TFA.  Purified 
product peak collected and lypholized as dry sample.  Mass determination was confirmed 
by MALDI-TOF MS and purity check by analytical C18 reverse-phase HPLC.  Reported 
95.6% pure GASGPFPQPELPYGC G0 tetramer construct was stored at -80
o 
C.  Average 
 





2.4.17 Synthesis of CGASGPFPQPELPYG G1 Octamer (N-terminus linked) 
A linker solution of succinimidyl-[(N-maleimidopropionamdio)- 
dodecaethyleneglycol]ester  (NHS-PEO12-Maleimide)  prepared  by  dissolving  6.0  mg 
NHS-PEO12-Maleimide in 200 uL acetonitrile and 100 uL distilled water. At 2 hour 
intervals, 2 uL of 20% G1 polyamidomine (G1 PAMAM) dendrimer in methanol was 
added into the linker solution.  A total of 10 uL G1 PAMAM solution was added into the 
linker solution. 30.0 mg CGASGPFPQPELPYG peptide was dissolved into 400 uL 
distilled water with 14 uL acetic acid.  Linker solution was added to the peptide solution, 
and left  the reaction for 12  hours.  Reaction mixture was first  purified using size- 
exclusion chromatography (SEC-3000 gel filtration column). Collected fraction was then 
injected into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical C18  reverse-phase HPLC.  CGASGPFPQPELPYG G1 octamer construct was 
stored at -80
o 
C. Average yields obtained were 8%. No reported purity. 
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2.4.18 Synthesis of GASGPCPQPELPYG G1 Octamer (P2-residue linked) 
A linker solution of succinimidyl-[(N-maleimidopropionamdio)- 
dodecaethyleneglycol]ester  (NHS-PEO12-Maleimide)  prepared  by  dissolving  6.0  mg 
NHS-PEO12-Maleimide in 200 uL acetonitrile and 100 uL distilled water. At 2 hour 
intervals, 2 uL of 20% G1 polyamidomine (G1 PAMAM) dendrimer in methanol was 
added into the linker solution.  A total of 10 uL G1 PAMAM solution was added into the 
linker solution. 30.0  mg GASGPCPQPELPYG peptide was  dissolved into  400  uL 
distilled water with 14 uL acetic acid.  Linker solution was added to the peptide solution, 
and left  the reaction for 12  hours.  Reaction mixture was first  purified using size- 
exclusion chromatography (SEC-3000 gel filtration column). Collected fraction was then 
injected into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical C18  reverse-phase HPLC.  CGASGPFPQPELPYG G1 octamer construct was 
stored at -80
o 





2.4.19 Synthesis of GASGPFPQPELPYGC G1 Octamer (C-terminus linked) 
 
A linker solution of succinimidyl-[(N-maleimidopropionamdio)- 
dodecaethyleneglycol]ester (NHS-PEO12-Maleimide) prepared by  dissolving 12.0  mg 
NHS-PEO12-Maleimide in 400 uL acetonitrile and 200 uL distilled water. At 2 hour 
intervals, 2 uL of 20% G1 polyamidomine (G1 PAMAM) dendrimer in methanol was 
added into the linker solution.  A total of 20 uL G1 PAMAM solution was added into the 
linker solution. 50.0 mg GASGPFPQPELPYGC peptide was dissolved into 500 uL 
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distilled water with 14 uL acetic acid.  Linker solution was added to the peptide solution, 
and left  the reaction for 18  hours. Reaction mixture was first  purified using size- 
exclusion chromatography (SEC-3000 gel filtration column). Collected fraction was then 
injected into semipreparative C18  reverse-phase HPLC column using water-acetonitrile 
gradient in 0.05-0.04% (v/v) TFA.  Purified product peak collected and lypholized as dry 
sample.  Mass determination was confirmed by MALDI-TOF MS and purity check by 
analytical C18  reverse-phase HPLC.  GASGPFPQPELPYGC G1 octamer construct was 
stored at -80
o 





2.5  Competitive Binding Assay 
125
I-labeled peptide (30,000 cpm; 1-5 nM) were incubated with DQ2 (1 µM) 
overnight  at  37
o
C  in  the  presence  of  a  mixture  of  protease  inhibitors. Various 
concentrations of the unlabeled peptides were added to inhibit binding of the 
125
I-labeled 
peptide. DQ2 molecules and peptides were separated on Sephadex G-50 Superfine 
(Pharmacia  Biotech)  mini  spin  columns. The  radioactivity  was  counted,  and  the 
concentrations of the competing peptides required to give 50% inhibition of binding of 





2.6  T Cell proliferation Assay 
 
HLA-DR3/DQ2 homozygous Epstein-Barr virus transformed B-lymphoblastoid 
cell  lines (CD114) were used as  antigen-presenting cells. The cells were either γ- 
irradiated or fixed with 1% paraformaldehyde for 10 minutes or with 0.05% 
glutaraldehyde for 90 seconds using 0.2 M glycine to quench the reaction.  The antigen 
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presenting cells were incubated with the appropriate peptides/multimer constructs 
overnight in 60 µL media containing 10% fetal bovine serum/2% human serum or 15% 
human serum, penicillin, and streptomycin at a cell density of 2 x 10
6 
cells/mL in 96-well 




50 µL of which was placed into a U-bottom 96-well plate.  An equal volume of T cells 
 
(50 µL of 1 x 10
6 
cells/mL) was added to each well, and cells were incubated at 37
o
C and 
5% CO2 for 48 hours, at which time 0.5 µCi/well of [methyl-
3
H] thymidine (Amersham, 
TRK120) or 1 µCi/well of [methyl-
3
H] thymidine (Hartmann Analytic) was added.  Cells 
were  incubated  for  an  additional  12-14  hours  and  then  frozen. After  thawing, 
incorporated thymidine was collected on a  filter mat (Wallac), using a  Tomtec cell 
harvester, and counted using a Wallac 1205 Betaplate or Wallac 1450 MicroBeta TriLux 
































3.1 Competitive Binding Assay on α-I gliadin Analogs 
 
GASGPFPQPELPYG (RY111) was  chosen as  the  monomer for  the multivalent 
library constructs.  The binding affinity of this peptide has a moderate IC50 among the 
range of IC50’s exhibited from the α-I gliadin analog set (Table 1).  A moderate binding 
affinity is desired because increases in binding affinity through a multivalency effect can 
be better observed with moderate binding affinity. 
 
                                                           17.01.2008   23.01.2008  28.01.2008 
   10-fold 
IC50 
(µM) 
   3-fold 
IC50 
(µM) 
    3-fold 
 IC50 
(µM) 
P1886 GASGPFPQPELPYG = RY111 
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         0,8        1,3       0,8 
P1887 GASGPAPQPELPYG = 
RY112 
         0,5          1       0,8 
P1888 GASGPEPQPELPYG = 
RY113 
         5,8      <1,67       0,6 
P1889 GASGPRPQPELPYG = 
RY114 
         1,3        2,2       1,7 
P1890 GASGPWPQPELPYG= 
RY115 
         0,8        1,3       0,8 
P1281 LQPFPQPELPY          2,9        4,8       2,7 
P198 KPLLIIAEDVEGEY          0,1        0,06      0,06 
 
Table 1:  Above α-I gliadin analogs were tested for binding to HLA-DQ2 molecules in a 
competitive binding assay with  the  IC50  values (µM) given  for  10-fold and  3-fold 
titrations.  P1281 is the positive control peptide and P198 is the negative control peptide. 














 3.2 T cell Proliferation Assay on α-I gliadin Analogs 
 
None of the α-I gliadin analog peptides illicit an immunogenic response in a T cell 
proliferation assay using T cell clone (TCC 380.E37). 
 





















0.01 0.1 1 10 100 
Conc peptide (µM) 
 
P1886 GASGPFPQPELPYG (RY111) 
P1887 GASGPAPQPELPYG (RY112) 
P1888 GASGPEPQPELPYG (RY113) 
P1889 GASGPRPQPELPYG (RY114) 
P1890 GASGPWPQPELPYG (RY115) 
P1281 LQPFPQPELPY 
 
Figure  3: T  cell  proliferation  assay on  the  α-I  gliadin  analog  peptides  at  various 
concentrations.  No immunogenic response from any of the peptides for the DQ2-α-I- 
specific  T  cell  clone  (TCC  380.E37). P1281  is  a  positive  control. (Courtesy  of 


































































































































































































































































































































































































































































































*Molar  abs. 
at 280nm 










Monomer RY-111 1,490 1,574.68 1,575.71 ~30% 98  
RY-211 1,490 1,427.61 1,428.64 ~30% 98  
RY-311 1,490 1,574.68 1,575.74 ~30% 97  
Dimer RY-121 3,230 3,298.06 3,298.68 31% 98  
RY-122 2,980 3,313.65 3,336.31 30% 97  
RY-123 2,980 3,303.74 3,307.65 53% 97  
RY-221 3,230 3,003.92 3,004.21 58% 98  
RY-222 2,980 3,020.29 3,020.23 48% 98  
RY-223 2,980 3,009.60 3,013.10 35% 98  
RY-321 3,230 3,298.06 3,293.90 46% 97  
RY-322 2,980 3,313.65 3,311.17 12% 96  
RY-323 2,980 3,303.74 3,300.20 39% 96  
Trimer RY-131 4,470 4,942.40 4,956.86 40% 99  
RY-231 4,470 4,501.19 4,507.44 25% 97  
RY-331 4,470 4,942.40 4,939.64 50% 96  
Tetramer RY-141 5,960 8,179.40 8,178.66 7% 98  
RY-241 5,960 7,591.12 7,588.95 28% 95  
RY-341 5,960 8,179.40 8,177.09 27% 96  
RY-441 5,960 6,064.19 6,067.02 < 1% 95  
Octamer RY-181 11,920 19,574.48 19,589.54 8% N/A  
RY-281 11,920 18,397.90 18,039.71 20% N/A  
RY-381 11,920 19,574.48 19,585.94 14% N/A  
 
Table 2:   Percentage Yield and purity of the multivalent library set, including calculated, 




3.4 Biological Assay on Multivalent Library 
 




antigen-presentation cells (APCs) were incubated with 10 µM 
 
of multivalent constructs, including the monomers.  DQ2-α-I specific T cell clone (TCC 
 
380.E2)  proliferation is a measure of the immunogenicity of the antigen presentation. 
All the constructs in the library, except the GASGPC(t-butyl)PELPYG monomer 
(RY211),  resulted  in  an  immunogenic  response  (Figure  5). Interestingly,  upon 
multimerization of RY211 monomer, there is increased immunogenicity.   Furthemore, 
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this increase in immunogenicity relative to the monomer is not uniform across the various 
multivalent constructs.  For example, of the three dimer constructs (RY221, RY222, and 
RY223), the dimer with the longest linker (19.9 Angstroms, DPDPB linker, RY221) has 
the highest immunogenicity.  Whereas the dimer with the shortest linker ( 13 Angstroms, 
BMH  linker,  RY222)  ,  shows  the  least  increase  in  immunogenicity. This  finding 
supports two assumptions:  1) the binding affinity of a multimer increases relative to a 
monomer and 2) the distance between two monomer epitopes in a dimer is critical to 
achieve enhanced binding. Moreover, the latter point may imply that the effect of 
increased affinity binding is not just simply due to an increase in “local concentration” of 
the epitopes, but rather simultaneous binding of the epitopes to mulitple targeted HLA- 
DQ2s (clustering effect).  If we ignore the clustering effect, it can be assumed that the 
increase in valency of a construct will increase its binding affinity due to higher “local 
concentration”. However, if clustering effect is added into the assumption, which is 
dependent on distance/orientation, increases in binding affinity cannot be evaluated on 
the basis of valency alone, but through both valency and optimal orientations. It is in this 
consideration that one can expect to see a construct of lower valency with optimal 
orientation having better binding affinity than a construct with higher valency but 
suboptimal  orientation. For  example,  the  DPDPB  dimer  (RY221)  exhibits  higher 
immunogenicty compared to the TMEA trimer (RY223). Despite the increase in valency 
from a dimer to a trimer, the trimer construct still has lower binding affinity.  Additional 
examples  are  the  tetramer  (RY241)  and  octamer  (RY281)  constructs  which  exhibit 
similar immunogenicity as the DPDPB dimer (RY221).   This can be partly explained 
through the clustering effect.  The trimer has a less optimal orientation for simultaneous 
50  
binding compared to the dimer, resulting in a lower binding affinity.  However, the 
tetramer and octamer binding affinities are similar to the dimer binding affinity because 
the opposing effects of increase in binding affinity due to valency and the less optimal 
binding  orientation/clustering  result  may  cancel  each  other  out. Although  the 
contribution of a higher valency in binding affinity is independent of the clustering effect, 
it is not possible to decipher the two effects independently in a T cell proliferation assay. 
The increase in binding affinity through an increase in valency without clustering effects 
can be masked by the steric hindrance of the multimer to T cell recognition.  This would 
show up as “no effect” in a T cell proliferation assay.  This is a limitation of using a T 
cell proliferation assay in studying multivalency effects. 
An α-I gliadin, LQPFPQPELPY, peptide (P1281) at 10 µM was used as a control 
in the T cell proliferation assay.   Other than GASGPFPQPELPYGC(t-butyl) (RY311) 




Figure 5:  Recognition of multivalent constructs by DQ2-α-I specific T cell clone (TCC 
380.E2).  The  peptides  were  tested  at  10µM.  P1281:  LQPFPQPELPY  (Courtesy  of 








antigen-presentation cells (APCs) were treated with 2.5 µM γ-I 
gliadin, PEQPQQSFPEQERP, epitope in the presence of varying concentrations of C(t- 
butyl)GASGPFPQPELPYG (RY111) –monomer, -dimer (RY121), -trimer (RY131), - 
tetramer (RY141), and –octamer (RY181) constructs. DQ2- γ-I specific T cell clone 
(TCC  423.1.3.8) proliferation was  a  measure of  the  multivalent blocking potential 
towards the antigen presentation of γ-I gliadin (Figure 6).  This subset of constructs from 
the multivalent library did not block the γ-I gliadin presentation on irradiated APCs.  T 
cell proliferation is the same across the different concentration of the multivalent 
constructs (RY111 monomer, RY121 dimer, RY131 trimer, and RY 141 tetramer, and 
RY181 octamer).  There are several possibilities that can explain this result.  The first is 














overall illicit similar immunogenic response.   The similar immunogenic response may 
imply  that  these  constructs  have  similar  binding  affinities. With  similar  binding 
affinities, this subset of multivalent constructs would be expected to block the γ-I gliadin 
presentation  in  a  similar  fashion. Secondly,  irradiated  APCs  can  have  biological 
processes such as endocytosis and MHC turnover that would interfere with the effects of 
blocking from the multivalent constructs. Endocytosis of the multivalent constructs can 
lead   into   endosomal-lysosomal  degradation   paths   that   render   the   constructs   as 
metabolized remnants of non-binders toward HLA-DQ2.  Alternatively, the multivalent 
constructs bind to HLA-DQ2 molecules on the cell surface, but due to MHC turnover, the 





T CC 423.1.3.8 (DQ2-γ -I specific) 
 
 











RY121 + P1213 2.5µM 
RY131 + P1213 2.5µM 
RY141 + P1213 2.5µM 









Figure 6: Inhibition of T-cell proliferation by the multivalent peptides. The T-cell clone 
423.1.3.8 (specific for the DQ2-γ-I gliadin epitope) was stimulated with 2.5µM 
PEQPQQSFPEQERP (P1213, DQ2-γ-I gliadin epitope) in the presence of increasing 
concentration of multivalent peptides RY111, RY121, RY131, RY141 and RY381. 
APC: Irradiated CD114.  (Courtesy of Ludwig 
Sollid and Elin Bergseng) 
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antigen-presentation cells (APCs) were treated with 2 µM γ-IV 
gliadin, FSQPEQEFPQPQ, epitope in the presence of varying concentrations of 
GASGC(t-butyl)FPQPELPYG (RY211) –monomer, -dimer (RY221), -trimer (RY231), - 
tetramer (RY241), and –octamer (RY281) constructs.  DQ2- γ-IV specific T cell clone 
(TCC 430.1.122) proliferation was a measure of the multivalent blocking potential 
towards the antigen presentation of γ-IV gliadin (Figure 7).   Although this multivalent 
subset inhibited anitgen presentation of γ-IV gliadin compared to the monomer, there was 
no difference in inhibition between dimer, trimer, tetramer, and octamer. Since the 
inhibition is the same among the multimers, it is likely that the increase in local 
concentration is responsible for the inhibition rather than a clustering effect.  The lack of 
effect due to clustering can be a result of non-optimal orientation of the multivalent 
construct as well as the fixed orientation of the HLA-DQ2 molecules.  It would be of 
interest to observe the immunogenic response of TCC 380.E2 (T cells used in Section 
 
3.4.1) towards this multivalent library subset using fixed APCs, since similar inhibition 
(Figure 7) would imply similar binding affinity. If this were true, the immunogenic 
response would be similar among this multivalent subset when using fixed APCs, unlike 
the differential immunogenic response profile seen with this same multivalent subset 





































P1963 (RY211)+1396 2µM 
P1968 (RY221)+1396 2µM 
P1975 (RY231)+1396 2µM 
P1978 (RY241)+1396 2µM 
P1982 (RY281)+1396 2µM 
P1396 2µM 
APC + T 
 
 
Figure 7:  Inhibition of T-cell proliferation by the multivalent peptides. The T-cell clone 
430.1.122 (specific for the DQ2-γ-IV gliadin epitope) was stimulated with 2µM 
FSQPEQEFPQPQ (P1396, DQ2-γ-IV  gliadin  epitope)  in  the  presence  of  increasing 
concentration of multivalent peptides RY211, RY221, RY231, RY241 and RY281. 
APC: Fixed CD114. (Courtesy of Ludwig Sollid 




3.5 Future Directions 
 
Although this  study did  not  demonstrate a  positive correlation with  increase in 
binding affinities and increase in valency, it did imply that a multimer has the capacity to 
enhance its binding affinity relative to the monomer (Section 3.4.3).  It is speculated that 
a linear association was not observed due to non-optimal topologies of the multivalent 
constructs. The  non-optimal  orientations  of  the  multivalent  constructs  prevent  the 
clustering effect because the energy barrier for simultaneous ligand binding to HLA-DQ2 
is too high.   This can be addressed with rational design involving ligand spacing and 
orientation of the multivalent construct.  Despite this supposed lack of clustering effect, 
the multivalent constructs still did not show any effect of increase in local concentration 
(through increases in valency) (Section 3.4.2).  It is possible that the range of valencies 
(dimer, trimer, tetramer, and octamer) is not great enough to showcase the enhanced 
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binding due to increase in local concentration.  In order to expand the range of valencies 
in the multivalent library, new synthetic chemical strategies must be explored. It is 
difficult to treat the effects of local concentration and clustering independently.  An 
increase in local concentration by increasing valency has the potential of added clustering 
effects   if   the   orientation/geometry  of   the   multivalent   construct   is   optimal   for 
simultaneous  ligand  binding. Of  course,  this  optimal  orientation/geometry  would 
certainly depend  on  the  valency. When  considering these  issues,  the  study of  the 
multivalency principle requires very careful rational design to ensure that the correct 
effects are being tested. 
 
Another important point to consider is the biological assays used to observe the 
multivalency  effect. The  main  biological  assay  used  in  this  study  is  the  T  cell 
proliferation assay.  This assay only measures the T cell proliferation response to antigen 
presentation.  But antigen presentation is a multifaceted phenomenon that goes beyond 
the simple model of a lock and key interaction between a ligand and a receptor.  MHC 
molecules can be turned over, peptides can be endocytosed and degraded, and MHC 
cluster moieties alter the T  cell  recognition (Wulfing, 2001). Furthermore, antigen 
presentation towards T cell recognition is T cell clone dependent.   Thus, biochemical 
assays such as a competitive binding assay may be more suited, initially, to investigate 
the multivalency effect.  After biochemical analyses, T cell proliferation assays can be 
used to validate the usefulness of such multivalent constructs. 
 
There  are  several  avenues for  further investigation in  the  multivalent principle. 
These considerations include the stability of the constructs, optimizing linker lengths, 
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wider spectrum of valencies, and polyvalency.  It is critical to evaluate the stability of the 
multivalent constructs because in the event of endocytoses and lysosomal fusion, these    
constructs are degraded into smaller constituents.  This degradation pathway needs to be 
corrected for when attempts are made in quantifying the influence of valency on affinity 
binding.  In  regards to  affinity binding, the  issue of  linker lengths plays  a  role  in 
simultaneous ligand binding of a multivalent construct.  By optimizing the linker lengths 
for a given valency, one can compare between valencies on its ability to competitively 
inhibit native epitopes. When showing the potential of the multivalent effect, it  
is important to demonstrate the difference in binding affinities with a wide range of 
valencies. A benefit of using higher valencies to show the multivalent effect is 
the opportunity to  use  lower  doses  to  achieve  similar  levels  of  inhibition  compared 
to constructs of lower valencies, but higher doses.  Low doses and high activity are prime 
initiatives in developing therapeutics.  Lastly, polyvalency is a topic of interest because it 
allows  multiple  targeting  through  different  ligands. Polyvalency follows the  same 
multivalency principle described previously, but instead of the principle applying to a 
single type of ligand, it is applicable to several different types of ligands on the same 
multivalent construct.  For example, a multivalent construct can have multiple inhibitory 
peptides targeted for HLA-DQ2 and multiple ligands/peptides that can interact and block 
CTLA4 (co-stimulator of T cell activation).  This results in a multi-level inhibition of 
HLA-DQ2 antigen presentation and T cell activation.   Polyvalency can also 
provide insight on the multivalent effect.  For instance, a multivalent construct can be 
optimized in linker length for a given valency in achieving a high affinity binding 
construct.  One peptide can be substituted into this multivalent construct and analyzed for 
the affect on its binding affinity. With respect to this substituted peptide, binding 
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affinity could be enhanced through this polyvalent construct.  Such a polyvalent 
construct proves useful when diverse T cell clone populations require minimal presence 
of any specific immunogen.  In continuing the study of the multivalent principle beyond 
what has been presented here, the future endeavors should lie in the realm of 
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C(t-butyl)GASGPFPQPELPYG: 0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 100 






GASGPC(t-butyl)PQPELPYG: 0  to  100% 80:20 ACN:H2O w/  0.04% TFA in  100 




GASGPFPQPELPYGC(t-butyl): 0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 100 






CGASGPFPQPELPYG DPDPB Dimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 




GASGPCPQPELPYG DPDPB Dimer:   0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 






GASGPFPQPELPYGC DPDPB Dimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 




CGASGPFPQPELPYG BMH Dimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 






GASGPCPQPELPYG BMH Dimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA 




GASGPFPQPELPYGC BMH Dimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 






CGASGPFPQPELPYG HBVS Dimer:   0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 




GASGPCPQPELPYG HBVS Dimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 






GASGPFPQPELPYGC HBVS Dimer:   0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 




CGASGPFPQPELPYG TMEA trimer:   0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 






GASGPCPQPELPYG TMEA trimer:  0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 




GASGPFPQPELPYGC TMEA trimer:   0 to 100% 80:20 ACN:H2O w/ 0.04% TFA in 






CGASGPFPQPELPYG G0 PAMAM tetramer:  0 to 100% 80:20 ACN:H2O w/ 




GASGPCPQPELPYG G0 PAMAM tetramer:   0 to 100% 80:20 ACN:H2O w/ 






GASGPFPQPELPYGC G0 PAMAM tetramer:  0 to 100% 80:20 ACN:H2O w/ 
0.04% TFA in 100 minutes at 0.2 mL/min. 
69  
APPENDIX B: MALDI-TOF MS (Peak of interest are shown in subpanels) 
 
NH2-C(t-butyl)GASGPFPQPELPYG (RY 111) 









NH2-GASGPC(t-butyl)PQPELPYG (RY 211) 





NH2-GASGPFPQPELPYGC(t-butyl) (RY 311) 









NH2-CGASGPFPQPELPYG DPDPB Dimer (RY 121) 




NH2-GASGPCPQPELPYG DPDPB Dimer (RY 221)   





NH2-GASGPFPQPELPYGC DPDPB Dimer (RY 321) 





NH2-CGASGPFPQPELPYG BMH Dimer (RY 122) 




NH2-GASGPCPQPELPYG BMH Dimer (RY 222) 







































NH2-GASGPFPQPELPYGC HBVS Dimer (RY 323) 





NH2-CGASGPFPQPELPYG TMEA Trimer (RY 131) 






NH2-GASGPCPQPELPYG TMEA Trimer (RY 231) 





NH2-GASGPFPQPELPYGC TMEA Trimer (RY 331) 





NH2-CGASGPFPQPELPYG G0 PAMAM Tetramer (RY 141) 





NH2-GASGPCPQPELPYG G0 PAMAM Tetramer (RY 241) 





NH2-GASGPFPQPELPYGC G0 PAMAM Tetramer (RY 341) 





NH2-GASGPFPQPELPYG MAPs Tetramer (RY 441) 





NH2-CGASGPFPQPELPYG G1 PAMAM Octamer (RY 181) 





NH2-GASGPCPQPELPYG G1 PAMAM Octamer (RY 281) 















APPENDIX C: Linker Lengths and PAMAM Core Span 
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